Company intelligence / Profile preview
Celyad Oncology
Mont-Saint-Guilbert, Wallonia, Belgiumcelyad.com ↗
- Ownership
- Private
- Employees
- ~19
- Development stage
- Phase 1
01
Overview
Until late 2022, Celyad Oncology was a clinical-stage biotech with several early-phase trials in allogeneic and autologous CAR-T therapies. Its lead programs included CYAD‑101 for metastatic colorectal cancer and CYAD‑211 for multiple myeloma. Both were discontinued after limited efficacy signals but proof-of-concept safety data for the shRNA platform. The company now focuses on research, technology development, and licensing its intellectual property estate.
- Therapeutic areas
- Oncology
- Modalities
- Chimeric Antigen Receptor T-cells (CAR-T)Allogeneic CAR-T (off-the-shelf)Autologous CAR-T (personalized)shRNA-based cell therapy
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
MSD/Merck & Co., Inc.: Clinical trial collaboration on KEYNOTE-B79 trial with pembrolizumab + CYAD–101 in mCRC patientsNovartis International AG – Licensing agreement related to US patents on allogenic CAR–T cells.Horizon Discovery/PerkinElmer – Collaboration/license agreements regarding use of shRNA reagents.
Beyond the preview
Go deeper on Celyad Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celyad Oncology.